Pencil beam scanning proton therapy for pediatric intracranial ependymoma

Carmen Ares^{1,2} · Francesca Albertini¹ · Martina Frei-Welte³ · Alessandra Bolsi¹ · Michael A. Grotzer⁴ · Gudrun Goitein¹ · Damien C. Weber^{1,5}

Received: 10 March 2015 / Accepted: 25 February 2016 / Published online: 5 March 2016
© Springer Science+Business Media New York 2016

Abstract To assess the clinical outcome and late side effect profile of pencil beam scanning proton therapy (PT) delivered to children with intracranial ependymoma. Between July-2004 and March-2013, 50 patients with intracranial ependymoma ($n = 46$, grade 3) received involved-field PT at Paul Scherrer Institute (PSI). Median age at time of PT was 2.6 years (range 1.1–15.2). Thirty-six patients had infratentorial and 14 supratentorial ependymomas. Seventeen patients presented with macroscopic residual disease after subtotal resection before starting PT (8 with ≤ 1.5 cc and 9 with > 1.5 cc residual tumor respectively). Forty-three (86 %) patients received post-operative chemotherapy before PT according to protocols; 44 (88 %) patients younger than 5 years required general anesthesia. Median prescribed dose was 59.4 Gy (RBE) (range 54–60) delivered in 1.8–2 Gy (RBE) per fraction. Late toxicity was assessed according to CTCAE v4.0. With a mean follow-up time of 43.4 months (range 8.5–113.7) seven patients experienced local failure (6 with infratentorial tumors and 1 with supratentorial tumor); four of the local failures were in patients with residual disease ≥ 1.5 cc at the time of PT and 3 without residual

macroscopic disease. Five patients died from tumor progression. Actuarial 5-year Local Control rates were 78 ± 7.5 % and 5-year OS rates were 84 ± 6.8 %. Three patients developed grade ≥ 3 toxicity: 2 developed unilateral deafness (infratentorial tumors infiltrating into the internal acoustic canal), one patient developed a fatal brainstem necrosis. Repeated general anesthesia in children younger than 5 years was delivered without complications. Our data indicate the safety and the effectiveness of PT for pediatric ependymomas. Local control and survival rates are encouraging considering the high grade histology in 92 % of the patients and the number of patients with residual tumor ≥ 1.5 cc. The rates of late effects compare favorably with published photon-treated cohorts.

Keywords Central nervous system · Intracranial pediatric ependymoma · Pencil beam scanning proton therapy · Tumor local control · Radiotherapy

Introduction

Intracranial ependymomas account for 5 to 8 % of pediatric brain tumors, the majority occurring in children younger than 4 years [1]. The best outcomes for localized disease are achieved combining maximal surgical resection followed by involved-field radiation therapy (RT) [2–12]. In such a young population having high chance of cure the late side effects of RT are of major concern. The possibility of delivering chemotherapy to avoid or delay RT in young children under the age of 3 years has been evaluated by different investigators, with inferior results [5, 8, 13–16]. In addition, in pediatric patients, the physical dose characteristics of protons translate on clinical advantages of reducing incidence and severity of late side effects.

✉ Carmen Ares
carmen.ares@hcuge.ch

¹ Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, Switzerland

² Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland

³ Department of Anesthesia, University Children's Hospital Zurich, Zurich, Switzerland

⁴ Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland

⁵ University of Bern, Bern, Switzerland

Several pediatric dose-comparative studies have demonstrated the dosimetric superiority of protons in comparison to external beam photon techniques including intensity modulated RT (IMRT), as proton have a finite range in tissue and optimally spare organs at risk in vicinity of the target volume, [17]. The most used method for the delivery of proton therapy (PT) is the passive-scattering technique [18]. In 1980, Kanai [19] proposed scanning a narrow pencil-beam in three-dimensions through the target volume. This concept of “pencil beam scanning” was further developed at Paul Scherrer Institute [20], where the first patient was treated on a pencil beam scanning gantry in 1996. The flexibility of the pencil beam scanning approach has been extended at PSI to deliver intensity-modulated proton therapy (IMPT) [21–23]. IMPT is the direct equivalent of IMRT with photons and has been successfully integrated into the clinical routine since its introduction in 1999. The pencil beam scanning method allows increasing the dose-conformation capabilities not only at the distal region of the target, but also to the proximal region of the target from a given field and allows to delivery IMPT efficiently. This increased conformation capabilities allows further sparing of the organs at risk located proximal to the target, compared with passive-scattering techniques. Up to now IMPT can be delivered efficiently only with pencil beam scanning methods.

This is the first report of the long-term results of the use of pencil beam scanning PT in a cohort of 50 patients treated with pencil beam scanning based PT for intracranial ependymoma.

Methods and materials

Patient characteristics

Between July 2004 and March 2013, 50 patients (36 male, 14 female) with histologically proven diagnosis of intracranial ependymoma WHO Grade 2 in 4 patients, Grade 3 in 46 patients were treated postoperatively with PT at PSI with curative intent. The tumors were infratentorial in 36 (72 %) patients and supratentorial in 14 (28 %) patients. Patients were referred from different Institutions from Switzerland and Europe. The majority (95 %) of the histological diagnosis were centrally reviewed according to HIT and COG protocols.

The median age of patients at the time of PT was 2.6 years (range 1.1–15.2), 44 patients (88 %) were <5 years requiring general anesthesia. Children were sedated with Propofol under spontaneous breathing [24].

The majority of patients have a performance status 0 prior to PT, only seven patients with posterior fossa tumors had some residual postoperative ataxia or cranial nerve palsy.

The mean follow-up (FU) time was 43.4 months (range 8.5–113.7 months). A summary of patient and tumor characteristics are summarized in Table 1.

PT treatment planning and delivery

All patients were immobilized using a combination of body cast and a vacuum-assisted bite-block system or thermoplastic mask. Patients with infratentorial tumors were immobilized in general in prone position and patients with supratentorial tumors in supine position (Fig. 1). Patient positioning was checked before every fraction, as published previously [25]. All children underwent 3D planning with CT and MRI fusion.

The postoperative tumor bed and residual tumor were identified as gross tumor volume (GTV). The clinical target volume (CTV) was defined as a 0.5–1 cm extension of the GTV restricted for anatomical boundaries. Figure 2 shows a representative dose distribution for patients with infratentorial and supratentorial ependymoma respectively.

Table 1 Patients and tumor characteristics and treatments details of 50 pediatric intracranial ependymomas treated with spot-scanning proton therapy

	N (%)
Number of patients	50
Gender	
Male	36 (72)
Female	14 (28)
Age at time of PT (months)	
12–24	13 (26)
25–36	18 (36)
37–48	10 (20)
49–60	3 (6)
>60	6 (12)
Tumor location	
Infratentorial	36 (72)
Supratentorial	14 (28)
Type of surgery	
GTR	33 (66)
STR ≤1.5 cc	8 (16)
STR >1.5 cc	9 (18)
Anesthesia	
Yes	44 (88)
No	6 (12)
Adjuvant Chemotherapy	
Yes	43 (86)
No	7 (14)
Median total dose [Gy (RBE)]	59.4 (range 54–60)

GTR gross total resection, *STR* subtotal tumor resection

Fig. 1 Immobilization examples for children under anesthesia for: (A) supratentorial tumors in supine with bite-block and (B1, B2) infratentorial tumors in prone with thermoplastic masks

The relative biologic effectiveness (RBE) factor for protons of 1.1 (relative to that of Co-60) was used, and proton doses were expressed in terms of Gy (RBE) [Gy (RBE) = proton Gy $\times$ 1.1] [26]. Patients received a median PTV dose of 59.4 Gy (RBE) [range 54–60 Gy (RBE)], in fractions of 1.8–2 Gy (RBE).

Patients were treated using the pencil beam scanning technique at the scanning gantry by using energy-degraded beams from the 590-MeV cyclotron until 2005 [20] and subsequently the dedicated 250-MeV cyclotron.

Proton dose was computed using a 3-dimensional dose calculation algorithm developed at PSI [27, 28]. Single-field uniform dose (SFUD) plans or intensity modulated proton therapy (IMPT) plans were used [29].

Dose constraints to organs at risk (OARs) were determined as maximum dose (D2) of 59.4 Gy (RBE) to the brainstem, 50.4 Gy (RBE) to the spinal cord (for patients

with infratentorial tumors with extension to the upper cervical spine), 54 Gy (RBE) to the optic chiasm and optic nerves and mean dose to at least one cochlea of 36 Gy (RBE). Treatment plans were optimized to maximize the coverage while observing OAR dose constraints.

Surgery, chemotherapy and residual disease

Prior to PT, maximal feasible resection was performed for all patients. Patients were always evaluated for a second look surgical resection in case of residual tumor. Gross tumor resection (GTR) was defined as no evidence of disease on immediate postoperative MRI. The residual tumor at the time of PT was defined on the planning MRI with a threshold value of 1.5 cc.

Eleven (22 %) patients performed a second look surgery prior to PT. Seventeen (34 %) patients presented with

Fig. 2 Representative spot-scanning PT plan for **a** infratentorial and **b** supratentorial ependymoma

macroscopic residual disease after subtotal tumor resection before starting PT; 8 patients presented with residual tumor ≤ 1.5 cc and 9 patients presented with residual tumor > 1.5 cc. Forty-three (86 %) patients received post-operative chemotherapy before starting PT according to international protocols, the mean interval time between initial diagnosis and initiation of PT was 7.5 months (range 2–25 months) due to this reason. The most common indications for chemotherapy were residual disease after resection and patient age under 3 years.

Clinical data

Variables from demographic, tumor and treatment characteristics included the patient's gender, date of birth, date of pathological diagnosis, histological grade (the majority based on review by central board pathologists), receipt of chemotherapy before RT, dates of surgical procedures, extent of surgical resection, RT dose, dates of start and completion of RT, location of relapse if any, date of relapse and date of last follow-up.

Follow-up evaluation

Patients were followed clinically and radiographically with serial brain and spine MRIs at regular intervals with neuroendocrinologic, ophthalmologic and auditory evaluations according to protocol recommendations. The neuroendocrinologic evaluation was systematically performed to all patients who received any dose of irradiation at the level of the hypothalamus or the pituitary gland. The

radiological evaluations were performed all the 3–4 months during the first 2 years after end of treatment and all the 6 months thereafter. For the patients that were not seen locally at the Proton Center we received the referral medical reports, the MRI examinations for review as well as questionnaires answered from the parents. No patient was lost to follow-up and we have a 100 % compliance rate regarding answered questionnaires from the families. Not all the patients performed regular neuropsychological evaluations because patients were referred from different institutions around Europe not being possible to have follow-up on the cognitive assessment using standardized measures for all the patients.

Radiological criteria for local tumor control were defined as no evidence of macroscopic tumor on consecutive MRI.

Pituitary hormone deficiencies were defined as below-normal levels by gender and age, in addition to clinical diagnosis by a pediatric endocrinologist. Auditory and ophthalmologic evaluations were performed by an audiologist and an ophthalmologist respectively.

Late adverse events were prospectively defined as side effects observed after 90 days following completion of PT and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grading system [30].

Statistical analysis

Local control (LC) was measured from the date of the start of PT to the date of local failure. Overall survival (OS) was

measured from the start of PT to the date of death, LC, and OS were censored for patients who had not failed or died at the date of their last follow-up, defined as the date of the most recent clinic note and/or MRI. LC and OS were estimated by the Kaplan–Meier method, using local recurrence and death as the respective failure endpoints. Two-sided *p* values for the potential impact of predictors on LC and OS were calculated using Fisher's exact test. All data analysis were carried out using the *StatSoft–Statistica* statistical package.

Results

Treatment outcomes

Local and distant control

With a mean follow-up time of 43.4 months (range 8.5–113.7), 7 patients (14 %) experienced in-field local failure; 6 with infratentorial tumors and 1 with a supratentorial tumor. This resulted in 5-year actuarial LC rates of 78.0 ± 7.5 % (Fig. 3). Four of the local failures were in patients presenting with residual disease ≥ 1.5 cc and 3 without residual macroscopic disease at the time of PT. Thirteen (76 %) out of the 17 patients presenting with macroscopic residual disease prior to irradiation responded completely to the irradiation; for a three (18 %) of these 17 patients a stabilization or a partial response of the disease was accomplished for several months with a mean interval time of 19 months (range 9–16 months) before progressing and 1 patient developed a progressive disease immediately after irradiation.

Two patients with local failure presented with synchronous microscopic CSF dissemination. One patient

presenting with locally controlled infratentorial tumor developed supratentorial metastasis. All the patients presenting with local or distant failure in our cohort were patients having received postoperative chemotherapy prior to irradiation.

Overall survival

Five patients (10 %) died of progressive disease following local or distant failure at a median time of 33 months (range 24–48). Hence, this resulted in actuarial OS rates at 5 years of 84 ± 6.8 % (Fig. 4).

As a result of the limited number of events, we were not able to perform statistical analyses to identify prognostic factors for LC or OS.

Late toxicity

Nineteen patients (38 %) developed 24 events of Grade 1 or Grade 2 late toxicities: 7 (14 %) patients developed permanent Grade 1 patchy alopecia or hair thinning. One patient (2 %) developed Grade 1 unilateral reduced hearing, 1 (2 %) patient developed Grade 1 concentration problems, and 9 (18 %) patients presented with a Grade 1 asymptomatic transient MRI changes of leukoencephalopathy. Three (6 %) patients presented with a permanent Grade 2 growth hormone deficiency requiring replacement and 3 (6 %) patients developed a permanent Grade 2 central hypothyroidism requiring replacement.

Three patients (6 %) developed grade ≥ 3 toxicity. Two patients with infratentorial tumors infiltrating into the internal acoustic canal developed definitive unilateral deafness as the ipsilateral cochlea was not spared due to the disease localization. One patient (3 years old girl) with an infratentorial ependymoma developed a fatal brainstem

Fig. 3 Actuarial local control rates

Fig. 4 Actuarial overall survival rates

necrosis 7.5 months after starting PT, confirmed on autopsy. This patient was initially treated with GTR and adjuvant chemotherapy and presented with tumor relapse under chemotherapy; a second surgery was performed and complicated with brain stem infarct and meningitis. At the time of the PT the girl presented with some residual ataxia only and was treated to a total dose of 59.4 Gy (RBE).

No secondary malignancies were observed during the follow-up period.

Discussion

Our results indicate the safety and the effectiveness of pencil beam scanning based postoperative PT for intracranial ependymomas. Estimates of 5-year PFS and OS from other retrospective photon series range from 41 to 58 and 54 to 71 %, respectively [2, 6–8, 31]. Merchant et al. [10] in their report on a prospective cohort of 153 patients with ependymoma found a 5-year PFS of 74 % and a 5-year OS of 85 %. MacDonald et al. [32] in their report on a cohort of 70 patients with localized ependymoma treated with passive scattering PT after 46 months of follow-up found a 3-year LC, progression free-survival and OS of 83, 76 and 95 % respectively. Our outcomes, are comparable to these reports, particularly considering that we had a lower rate of GTRs (66 vs. 81.7 % in the Merchant's series and 66 % in the MacDonald's series) and higher rate of WHO Grade 3 tumors (96 vs. 55 % in the Merchant series and 47 % in the MacDonald series) even if the issue of histology as prognostic factor in ependymoma is not resolved and there is some evidence from literature that European pathologist tend to have more Grade 3 tumors than their North American colleagues.

In our cohort 43 (86 %) patients received postoperative chemotherapy prior to irradiation according to protocols, prolonging the interval time between initial diagnosis and initiation of PT to a mean time of 7.5 months (range 2–25 months). Merchant et al. [9] reported a negative impact of prolonged chemotherapy prior to irradiation. In our cohort all the relapses were in patients having received chemotherapy but we cannot conclude that prolonged chemotherapy prior to radiotherapy has a negative impact on outcome as only seven patients in our series did not receive postoperative chemotherapy.

We were not able to perform a failure analysis based on potential prognostic factors because of the small number of events observed. Cox proportional hazards regression requires at least ten events per risk factor to produce accurate estimates [33].

Many previous studies that have emphasized the importance of aggressive removal of the primary tumor [2, 6, 8, 10–12, 15]. We report a rate of GTR similar to other

series, but not as high as that of Merchant et al., and MacDonald et al., mainly because of differences in the rate of second surgery. In the Merchant's 2009 series, 66 patients (43.1 %) underwent a second surgery, compared with 16 (23 %) in the MacDonald's series and 11 (22 %) in our series. The decision to recommend additional surgery remains challenging and is frequently limited by anatomical constraints and the level of morbidity considered acceptable by the parents and the physicians. Recently Morris et al. [34] established that more than one surgical procedure is safe for most patients. We advocate second-look surgery whenever required and feasible before PT.

The role of other prognostic factors is less clear. In some series anaplastic histology has been shown to worsen OS and PFS, including the large prospective cohort studied by Merchant et al. [4, 6, 8, 10–12]. Other series, similar to our report, did not find worse outcome [7, 35]. These differences may result from variation in the pathological interpretation of anaplasia and lack of statistical power. The evaluation of genetic profiles may better characterize prognostic subgroups [12, 36] in the future.

The average age of the patients in our cohort is relatively young. The reason is that patients were referred from different Institutions around Switzerland and Europe and due to our limited capacity the younger patients were given priority. Some studies, with the exception of Merchant's study [2, 7, 8, 31], found worse survival outcomes among patients under 3 years of age. This finding is probably related to the former common practice of delaying or omitting RT for this population. The benefit of RT in children under 3 years of age and the limited efficacy of chemotherapy to delay RT is well established, and post-operative conformal RT should continue as the standard of care for all ages [10, 11, 15, 16].

Opposite to Merchant et al., we did not detect that the incidence of distant failures increases relatively to the incidence of local failure. Modern series report a cumulative incidence of distant failures between 10 and 15 % over 3–5 years (6 % in our series) [3, 4, 6].

We report low rates of overall toxicities. Concerning the endocrinologic toxicity, in our series only three patients (6 %) developed laboratory evidence of growth hormone deficiency or central hypothyroidism requiring hormonal replacement, both of which are common complications of focal photon radiotherapy [37–39]. Merchant et al., in a prospective study of pediatric patients receiving focal photon RT for localized brain tumors, found a correlation of dose to the hypothalamus and growth hormone deficiency. A mean dose below 16.1 and 5 Gy limited the risk to 50 % and to below 20 % respectively [40]. In the MacDonald et al. series 1 out of 32 patients (3 %) with thyroid hormone follow-up developed laboratory evidence of central hypothyroidism and 2 out of 25 patients (8 %)

with growth hormone follow-up were diagnosed of growth hormone deficiency.

Relative cognitive stability after conformal photon therapy for patients with ependymoma has already been established [41–43]. In addition, theoretical quantitative modeling predicted a benefit for protons from the decreased volume of temporal lobes and cerebrum receiving intermediate and high doses [44]. In our series concerning the cognitive outcomes we preferred not to describe the data available for only a part of the cohort as not the full cohort performed regular neuropsychological evaluation, and so far into the partial cohort who has already performed regular testing there are not significant changes and the will be part of future updated analysis with a larger cohort. That happens because patients were referred from different institutions around Europe not being possible to have follow-up on the cognitive assessment using standardized measures for all the patients. In the other hand all the children were schooled and only one patient treated for a supratentorial tumor reported concentration problems described by parents and teachers.

We had no cases of secondary malignancies.

Although several prior studies have described imaging changes after PT in the brain of adult patients treated for skull base tumors [45–48], description of PT-related imaging findings in the brain in pediatric patients is limited. In our series 9 (18 %) patients developed asymptomatic transient MRI changes (signal abnormalities and enhancement) between 2 and 11 months after completion of PT. Sabin et al [49] described that 8 of 17 young children (47 %) with localized brain tumors treated with PT as part of a prospective protocol developed transient MRI changes at a median time of 3.9 months after the completion of PT. Those were mostly transient signal abnormalities and enhancement in brain parenchyma consistent with radiation-induced effects on normal-appearing tissue. The median time to resolution or the beginning of resolution of the imaging changes was 2.3 months. Correlation with PT planning data revealed that the areas of imaging abnormality were located within or adjacent to the volume that received the highest radiation dose. Radiologists should be aware of these findings as these signal changes and enhancement may resemble the imaging findings of tumor pseudoprogression.

In our cohort with a mean follow-up time of 43.4 months, 27 patients (54 %) were followed for more than 36 months and only 14 patients (28 %) were followed for less than 18 months. Longer follow-up is still required to provide more mature data concerning the outcome of pencil beam scanning PT, especially concerning the long term outcome on toxicities, as one of the major potential benefits of proton therapy compared with standard conformal techniques with photons is the improvement of the

long term quality of life reducing the incidence and the severity of the toxicities on long survivors.

The distinct physical properties of protons allow for complete sparing of normal tissues beyond the end range of the proton beam. The use of pencil beam scanning and the use of IMPT as available for clinical use at PSI further improves the conformality and sparing of normal tissues upon that which can be achieved with passive scattering proton radiotherapy obtaining further sparing of normal tissues and the entrance of the pencil beams translating in potential further reduction of rates of toxicity [17].

The present study represents the largest clinical series of pediatric intracranial ependymomas treated with pencil beam scanning PT. The treatment was very well tolerated, with minimal acute toxicity, low morbidity profile and excellent LC and OS rates.

Conclusions

Our study contributes to the small but growing body of evidence demonstrating the safety and the effectiveness of pencil beam scanning based PT for treating pediatric intracranial ependymomas. Pencil beam scanning technology was applied routinely and without technical difficulties or complications in this young patient population.

Local control and survival rates are encouraging considering the high grade histology in 92 % of the patients and the number of patients with residual tumor ≥ 1.5 cc (18 %). Furthermore, rates of late effects from PT compare favorably to published reports of photon-treated cohorts and comparable to published report of passive scattering PT treated cohort. We have established outcome data for a cohort of patients treated homogeneously.

References

1. Central brain tumor registry of the United States. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008 (March 23, 2012 Revision). Hinsdale Author; 2012
2. Perilongo G, Massimino M, Sotti G et al (1997) Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. *Med Pediatr Oncol* 29(2):79–85
3. Merchant TE, Haida T, Wang MH, Finlay JL, Leibel SA (1997) Anaplastic ependymoma: treatment of pediatric patients with or without craniospinal radiation therapy. *J Neurosurg* 86(6): 943–949
4. Schild SE, Nisi K, Scheithauer BW et al (1998) The results of radiotherapy for ependymomas: the Mayo Clinic experience. *Int J Radiat Oncol Biol Phys* 42(5):953–958
5. Timmermann B, Kortmann RD, Kuhl J et al (2000) Combined postoperative irradiation and chemotherapy for anaplastic

- ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. *Int J Radiat Oncol Biol Phys* 46(2):287–295
6. Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M (2002) Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. *J Neurooncol* 56(1):87–94
 7. Mansur DB, Perry A, Rajaram V et al (2005) Postoperative radiation therapy for grade II and III intracranial ependymoma. *Int J Radiat Oncol Biol Phys* 61(2):387–391
 8. Shu HK, Sall WF, Maity A et al (2007) Childhood intracranial ependymoma: twenty-year experience from a single institution. *Cancer* 110(2):432–441
 9. Merchant TE (2009) Three-dimensional conformal radiation therapy for ependymoma. *Childs Nerv Syst* 25(10):1261–1268
 10. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. *Lancet Oncol* 10(3):258–266
 11. Koshy M, Rich S, Merchant TE, Mahmood U, Regine WF, Kwok Y (2011) Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. *J Neurooncol* 105(3):583–590
 12. Phi JH, Wang KC, Park SH et al (2012) Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. *J Neurooncol* 106(3):619–626
 13. Needle MN, Molloy PT, Geyer JR et al (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. *Med Pediatr Oncol* 29(1):28–32
 14. Merchant TE, Fouladi M (2005) Ependymoma: new therapeutic approaches including radiation and chemotherapy. *J Neurooncol* 75(3):287–299
 15. Timmermann B, Kortmann RD, Kuhl J et al (2005) Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. *Radiother Oncol* 77(3):278–285
 16. Zacharoulis S, Levy A, Chi SN et al (2007) Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. *Pediatr Blood Cancer* 49(1):34–40
 17. MacDonald SM, Safai S, Trofimov A et al (2008) Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. *Int J Radiat Oncol Biol Phys* 71(4):979–986
 18. Koehler AM, Schneider RJ, Sisterson JM (1977) Flattening of proton dose distributions for large-field radiotherapy. *Med Phys* 4:297–301
 19. Kanai T, Kawachi K, Kumamoto Y et al (1980) Spot scanning system for proton radiotherapy. *Med Phys* 7:365–369
 20. Pedroni E, Bacher R, Blattmann H et al (1995) The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. *Med Phys* 22:37–53
 21. Lomax A (1999) Intensity modulation methods for proton therapy. *Phys Med Biol* 44:185–205
 22. Lomax AJ, Boehringer T, Coray A et al (2001) Intensity modulated proton therapy: a clinical example. *Med Phys* 28:317–324
 23. Lomax AJ, Pedroni E, Rutz H, Goitein G (2004) The clinical potential of intensity modulated proton therapy. *Z Med Phys* 14:147–152
 24. Frei-Welte M, Weiss M, Neuhaus D et al (2012) Pediatric anesthesia for proton radiotherapy : medicine remote from the medical centre. *Anaesthesist* 61(10):906–914
 25. Weber DC, Rutz HP, Pedroni ES et al (2005) Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. *Int J Radiat Oncol Biol Phys* 63:401–409
 26. Paganetti H, Niemierko A, Ancukiewicz M et al (2002) Relative biological effectiveness values for proton beam therapy. *Int J Radiat Oncol Biol Phys* 53:407–421
 27. Lomax AJ, Boehringer T, Bolsi A et al (2004) Treatment planning and verification of proton therapy using spot scanning: initial experiences. *Med Phys* 33:3150–3157
 28. Lomax AJ, Pedroni E, Schaffner B, Tourovski A et al. (1996) 3D treatment planning for conformal proton therapy by spot scanning. Proceedings of 19th LH Gray conference (BIR Publishing London) 67–71
 29. Lomax AJ (2008) Intensity modulated proton therapy. In: Delaney T, Kooy H (eds) *Proton and charged particle radiotherapy*. Lippincott Williams & Wilkin, Boston
 30. Cancer therapy evaluation program. Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC). National Institutes of Health. http://ctep.info.nih.gov/reporting/ctc_v4.0.html
 31. Jaing TH, Wang HS, Tsay PK et al (2004) Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. *J Neurooncol* 68(3):255–261
 32. MacDonald SM, Sethi R, Lavally B et al (2013) Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. *Neuro Oncol* 15(11):1552–1559
 33. Concato J, Peduzzi P, Holford T et al (1995) Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy. *J Clin Epidemiol* 48:1495–1501
 34. Morris EB, Li C, Khan RB et al (2009) Evolution of neurological impairment in pediatric infratentorial ependymoma patients. *J Neurooncol* 94(3):391–398
 35. Goldwein JW, Leahy JM, Packer RJ et al (1990) Intracranial ependymomas in children. *Int J Radiat Oncol Biol Phys* 19(6):1497–1502
 36. Mack SC, Taylor MD (2009) The genetic and epigenetic basis of ependymoma. *Childs Nerv Syst* 25(10):1195–1201
 37. Rappaport R, Brauner R (1989) Growth and endocrine disorders secondary to cranial irradiation. *Pediatr Res* 25(6):561–567
 38. Hancock SL, McDougall IR, Constine LS (1995) Thyroid abnormalities after therapeutic external radiation. *Int J Radiat Oncol Biol Phys* 31(5):1165–1170
 39. Merchant TE, Goloubeva O, Pritchard DL et al (2002) Radiation dose-volume effects on growth hormone secretion. *Int J Radiat Oncol Biol Phys* 52(5):1264–1270
 40. Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH (2011) Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. *J Clin Oncol* 29(36):4776–4780
 41. Merchant TE, Mulhern RK, Krasin MJ et al (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. *J Clin Oncol* 22(15):3156–3162
 42. Conklin HM, Li C, Xiong X, Ogg RJ, Merchant TE (2008) Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. *J Clin Oncol* 26(24):3965–3970
 43. Di Pinto M, Conklin HM, Li C, Xiong X, Merchant TE (2010) Investigating verbal and visual auditory learning after conformal radiation therapy for childhood ependymoma. *Int J Radiat Oncol Biol Phys* 77(4):1002–1008
 44. Merchant TE, Kiehna EN, Li C, Xiong X, Mulhern RK (2005) Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. *Int J Radiat Oncol Biol Phys* 63(5):1546–1554
 45. Debus J, Hug EB, Liebsch NJ et al (1997) Brainstem tolerance to conformal radiotherapy of skull base tumors. *Int J Radiat Oncol Biol Phys* 39:967–975

46. Santoni R, Liebsch N, Finkelstein DM et al (1998) Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. *Int J Radiat Oncol Biol Phys* 41:59–68
47. Miyawaki D, Murakami M, Demizu Y et al (2009) Brain injury after proton therapy or carbon ion therapy for head-and-neck cancer and skull base tumors. *Int J Radiat Oncol Biol Phys* 75:378–384
48. Pehlivan B, Ares C, Lomax AJ et al (2012) Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors. *Int J Radiat Oncol Biol Phys* 83(5):1432–1440
49. Sabin ND, Merchant TE, Harreld JH et al (2013) Imaging changes in very young children with brain tumors treated with proton therapy and chemotherapy. *AJNR Am J Neuroradiol* 34(2):446–450